Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management
- 547 Downloads
Purpose of review
This review describes cardiotoxicity associated with adoptive T cell therapy and immune checkpoint blockade.
Cardiotoxicity is a rare but potentially fatal complication associated with novel immunotherapies. Both affinity-enhanced and chimeric antigen receptor T cells have been reported to cause hypotension, arrhythmia, and left ventricular dysfunction, typically in the setting of cytokine release syndrome. Immune checkpoint inhibitors are generally well-tolerated but have the potential to cause myocarditis, with clinical presentations ranging from asymptomatic cardiac biomarker elevation to heart failure, arrhythmia, and cardiogenic shock. Electrocardiography, cardiac biomarker measurement, and cardiac imaging are key components of the diagnostic evaluation. For suspected myocarditis, endomyocardial biopsy is recommended if the diagnosis remains unclear after initial testing.
The incidence of immunotherapy-associated cardiotoxicity is likely underestimated and may increase as adoptive T cell therapy and immune checkpoint inhibitors are used in larger populations and for longer durations of therapy. Baseline and serial cardiac evaluation is recommended to facilitate early identification and treatment of cardiotoxicity.
KeywordsImmunotherapy Cardiotoxicity Adoptive T cell therapy Cytokine release syndrome Immune checkpoint inhibitor Myocarditis
Compliance with Ethical Standards
Conflict of Interest
Aarti Asnani declares that she has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 6.Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720–4.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(6):540–9.CrossRefGoogle Scholar
- 13.•• Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863–71. This detailed case report described two patients treated with T cells expressing an affinity-enhanced receptor against MAGE-A3 who developed cardiotoxicity attributed to cross-reactivity with the skeletal muscle protein titin. CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(33):4199–206.CrossRefGoogle Scholar
- 36.•• Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–55. This detailed case report described two patients treated with a combination nivolumab and ipilimumab therapy who developed fulminant autoimmune myocarditis. CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Tajiri K, Aonuma K, Sekine I. Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol. 2017:1–6.Google Scholar
- 39.•• Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136(21):2085–7. This observational study described clinical characteristics, treatments, and outcomes in a series of 30 patients with ICI cardiotoxicity. CrossRefPubMedGoogle Scholar